CytoDyn in Talks with FDA After Unblinding Trial Data for Severe-to-Critically Ill COVID-19 Patients

 CytoDyn expects to release CD12 data and complete discussions with various regulatory agencies within 2 to 3 weeks

CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the CD12 COVID-19 trial data has been unblinded and the results will be reported when the Company has concluded its ongoing discussions with regulators.

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented, “We are eager to reach conclusion in our discussions with all the regulatory agencies for the path going forward and will release the details of our data and the results of our discussions with regulatory agencies in the coming weeks.” Details of the Company’s ongoing discussions with the regulatory agencies are confidential.

https://finance.yahoo.com/news/cytodyn-discussions-u-fda-mhra-110000789.html